Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2014 | 06-2014 | 03-2014 | 12-2013 | 09-2013 | |
| Sales | 14,606 | 18,385 | 11,966 | 12,498 | 16,013 |
| Cost of Goods | 5,141 | 5,924 | 5,520 | 3,540 | 683 |
| Gross Profit | 9,465 | 12,461 | 6,446 | 8,958 | 15,330 |
| Operating Expenses | 28,632 | 28,325 | 32,185 | 30,822 | 34,507 |
| Operating Income | -19,026 | -14,940 | -25,219 | -21,324 | -18,494 |
| Interest Expense | 1,376 | 1,451 | 1,376 | 727 | 850 |
| Other Income | 122 | 118 | 47 | 64 | 52 |
| Pre-tax Income | -20,280 | -16,273 | -26,548 | -21,987 | -19,292 |
| Net Income Continuous | -20,280 | -16,273 | -26,548 | -21,987 | -19,292 |
| Net Income | $-20,280 | $-16,273 | $-26,548 | $-21,987 | $-19,292 |
| EPS Basic Total Ops | -0.16 | -0.13 | -0.22 | -0.20 | -0.17 |
| EPS Basic Continuous Ops | -0.16 | -0.13 | -0.22 | -0.19 | -0.17 |
| EPS Diluted Total Ops | -0.16 | -0.13 | -0.22 | -0.20 | -0.17 |
| EPS Diluted Continuous Ops | -0.16 | -0.13 | -0.22 | -0.19 | -0.17 |
| EBITDA(a) | $-18,187 | $-12,775 | $-25,857 | $-20,690 | $-17,874 |